MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
CNSP CNS Pharmaceuticals
- 0.1080
- -0.0020-1.82%
Close Dec 20 16:00 ET
- 0.1124
- +0.0044+4.07%
Post 20:01 ET
6.21MMarket Cap0.00P/E (TTM)
0.1200High0.1008Low4.81MVolume0.1050Open0.1100Pre Close528.01KTurnover8.52%Turnover Ratio0.00P/E (Static)57.49MShares70.000052wk High1.86P/B6.09MFloat Cap0.095552wk Low--Dividend TTM56.38MShs Float8534.8500Historical High--Div YieldTTM17.46%Amplitude0.0950Historical Low0.1090Avg Price1Lot Size
CNS Pharmaceuticals News
CNS Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
CNS Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2024 Financial Results Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025
CNS Pharmaceuticals | 10-Q: Q1 2024 Earnings Report
CNS Pharmaceuticals | 10-K: FY2023 Annual Report
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
CNS Pharmaceuticals | 10-Q: Q3 2023 Earnings Report
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
CNS Pharmaceuticals | 10-Q: Q2 2023 Earnings Report
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
CNS Pharmaceuticals | 10-Q: Q1 2023 Earnings Report
CNS Pharmaceuticals | 10-K/A: Annual report (Amendment)
CNS Pharmaceuticals | 10-K: FY2022 Annual Report
CNS Pharmaceuticals | 10-Q: Q3 2022 Earnings Report
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
CNS Pharmaceuticals | 10-Q: Q2 2022 Earnings Report
CNS Pharmaceuticals | 8-K: CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
CNS Pharmaceuticals | 10-Q: Q1 2022 Earnings Report
CNS Pharmaceuticals | 10-K/A: Annual report (Amendment)
CNS Pharmaceuticals | 10-K: FY2021 Annual Report
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.